Letter to
Unitholders
will gain the financial ability to seek such
specialised medical treatments. The type of
lifestyle diseases that are occurring within
the Indian population has also increased
with the rise in affluence among the mass
population. In particular, cancer and cardic
related diseases have been on the ascent,
and in certain Clinical Establishments
such as the Mulund and Mohali Clinical
Establishments which offer specialised
medical treatments for oncology, we have
seen its average revenue per operating bed
(“ARPOB”) grow.
Whilst management together with FHL
is focusing more of RHT’s Clinical
Establishments on the provision of higher
end medical treatments, we expect the rest
of the competition to be also moving in the
same direction. In FY2015 alone, we had
seen a number of single speciality hospitals
being set up in India. A single specialty
hospital is dedicated to the provision of
one line of medical discipline like oncology,
cardiology or ophthalmology and day-care
surgery. Some of the recent entrants to the
single speciality hospital segment in India
include Frontier Lifeline Hospital
6
and
NarayanaHrudayalaya
7
, which are dedicated
only to the treatment of cardiology and
Vasan Healthcare Group
8
whose speciality
is in treatment of eye ailments.
In addition to multi-speciality hospitals,
RHT together with FHL, will also bemoving
into the single speciality hospital space when
one of our two existing development projects
is completed in FY2016. At present, more
than 97% of RHT’s Clinical Establishments
are multi-speciality hospitals. However
with the completion of the Ludhiana
Greenfield Clinical Establishment in
FY2016, it will focus solely on providing
mother and child medical programmes.
We are optimistic about the plans we have
ahead for RHT and we will work with
our operator FHL to continue our push
into provision of more specialty medical
treatments at our Clinical Establishments.
ACKNOWLEDGEMENTS
To round off a good year, we would
like to thank our fellow Directors, the
management, the employees for their
dedication and hard work. We would also
like to thank our sponsor, FHL, our business
partners including our bankers, lawyers and
auditors for their unwavering support. We
wish to close off by expressing our sincere
gratitude to our unitholders for your
continued support and confidence in us.
We look forward to continuing our dialogue
with you, and we will strive to continue to
deliver consistent stable distributions in the
years to come.
MR GURPREET SINGH DHILLON
Chief Executive Officer and
Executive Director
25 June 2015
MR RAVI MEHROTRA
Executive Chairman and
Executive Director
25 June 2015
1
For further details, please refer to the Financial and
Operational Review on page 7 of this annual report.
receiving its distributions commencing 1 April 2015.
2
Sponsor Waiver – Fortis Healthcare Ltd (“FHL”), the
sponsor of RHT, had waived its entitlements to the
distributions from the public listing of RHT on
19 October 2012 to 31 March 2014. It started
receiving its distributions commencing 1 April 2015.
3
Total return assuming that RHT units were acquired
on 1 April 2014 at closing unit price of S$0.84.
4
“After 30 years of coalition, unfamiliarity of one-party
rule” – The Indian Express, 20 May 2014.
5
"India's healthcare sector to grow to $158.2 billion
by 2017" – The Economic Times, 2 December 2013.
6
7
8
ANNUAL REPORT FY2015
15
